As it continues with its small to medium-sized biotech deals, Gilead Sciences has put down $275 million for a 49.9% share in immuno-oncology biotech Pionyr Immunotherapeutics with the option to buy it out completely should it pass muster in early clinical tests.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,